Moderna reports that as of Friday, August 21, the Phase 3 “Cove” study has enrolled 13, 194 participants as of 5:00PM ET. The company makes significant progress in its quest for 30,000 participants in this pivotal Phase 3 study. In the spirit of transparency, the Cambridge, MA biotech company lists all of the study’s trial sites as well as diversity scores for the study thus far. The study has a ways to go as at present Black, Latinx, American India, Alaskan Native participants make up approximately 18% of all study participants. They will need to double this proportion to meet the national equivalent.
Moderna, the National Institutes of Health (NIH) and researchers in the COVE study are trying to find a solution to the current pandemic. The purpose of this study is to test Moderna’s vaccine candidate (mRNA-1273) that may prevent illness after exposure to the SARS-CoV-2 virus, which causes COVID-19. By enrolling in this study, participants are contributing to a potential solution that could help to solve this global health crisis.
Call to Action: To participate, click here for a site near you.